A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
30actual
Sites
13
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-10 | actual | When the study began enrolling |
| Primary completion | 2026-05-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-12 | actual | The whole study's end, after follow-up |
| First posted | 2024-11-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Carcinoma, Pancreatic Ductal
- Colorectal Neoplasms
- Carcinoma, Non-Small-Cell Lung
Interventions
- Drug: PF-07985045 — also filed as PF-5045
- Combination product: Gemcitabine — also filed as Gemzar
- Combination product: Nab-paclitaxel — also filed as Abraxane
- Combination product: Cetuximab — also filed as Erbitux
- Combination product: Fluorouracil — also filed as 5-FU, 5-fluorouracil
- Combination product: Oxaliplatin — also filed as Eloxatin
- Combination product: Leucovorin — also filed as Folinic Acid, Wellcovorin, calcium folinate, Leucovorin Calcium
- Combination product: Bevacizumab — also filed as Zirabev, Avastin
- Combination product: Pembrolizumab — also filed as Pembro, Lambrolizumab, MK-3475, Keytruda
- Combination product: Sasanlimab — also filed as PF-06801591
- Combination product: pemetrexed — also filed as Alimta
- Combination product: Cisplatin — also filed as Platinol, Cisplatinum, neoplatin
- Combination product: Paclitaxel — also filed as Taxol, Onxol
- Combination product: Carboplatin — also filed as Paraplatin, Stricarb
- Combination product: PF-07284892 — also filed as ARRY-558
Primary outcomes
what the primary-completion date above is the date OFPart 1 & 2: Incidence of Adverse Events (AEs)
measured Start of treatment up to 30 days after last dose or start of new anticancer therapy (whichever occurs first)
PART 1 & 2: Number of participants with laboratory abnormalities
measured From start of treatment up to 30 days after last dose or start of new anticancer therapy, whichever occurred first
Part 1 & Part 2 (Dose Escalation Only): Number of participants with Dose-limiting toxicities (DLT)
measured Baseline up to 28 days
Part 2: Objective Response - Number of Participants With Objective Response (alone or in combination)
measured Baseline and every 8 to 12 weeks through time of confirmed disease progression, death, unacceptable toxicity, or through study completion, approximately 2 years'
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed